Ilya Pharma at US Military Health System Research Symposium

Ilya Pharma has been invited to present its ILP100 accelerated wound healing therapy at the US Military Health System Research Symposium (MHSRS) 2021, to be held August 23-26 at the Gaylord Convention Center in Florida. Results for the company’s first in human trial were released earlier this year and it has recently received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds.

During its Cellular Therapeutics for Treatment of Shock and Trauma session, Ilya will report on how this new-in-class drug candidate of engineered Limosilactobacillus reuteri bacteria produces and releases the key human chemokine CXCL12 at the actual wound site. After delivery, ILP100 enhances the healing properties of immune cells in the wound.

Ilya has now been granted permission in Sweden to conduct a Phase II trial commencing in the third quarter of 2021.

Image credit: Diana Polekhina

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free